COMPANY RESEARCHPAQ develops KRAS degraders. The registered Phase 1 PT0253 study is in advanced solid tumors with KRAS G12D mutations. Historical autophagy positioning was not substituted for current technical disclosures.
$77 million is the total Series B, including the original $39 million. It is neither incremental extension proceeds nor lifetime cumulative company financing.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
NCT06797336 registers a PAQ-sponsored Phase 1 PT0253 monotherapy study, with an actual start date of 2024-12-19. The website identifies a KRAS degradation approach.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| PT0253 | KRAS G12D · Advanced solid tumors with KRAS G12D mutations | Phase 1 | Clinical registration exists; public results not confirmed in this review |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
PAQ Therapeutics plans to present the first clinical findings for selective KRAS G12D degrader PT0253 at ENA 2026 in Barcelona on November 20. The oral presentation will draw on an ongoing Phase 1 study in advanced solid tumors; a separate poster covers preclinical work. The announcement did not disclose quantitative efficacy results.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.